16-18 July 2018 | Boston

 

Hera Biolabs

Hera Biolabs, Inc., is an innovative pre-clinical contract research organization [CRO] utilizing cutting-edge gene-editing technologies to create novel in vivo models for oncology.  Given our mission to accelerate cancer research and drug development, we focus upon rat models to deliver translationally-relevant,  high-quality results.

Using proprietary technologies, Hera built the SRGTM Platform, a double knockout Sprague-Dawley rat engineered for T-cell, B-cell, and NK cell deficiency.  Our first SRG model is the OncoRat®, uniquely suited for xenograft studies given its excellent tumor take-rates and ability to deliver masses 10x that of mouse models in half the time – all without the increased risk of genetic drift from multiple passages as observed in mice.

To facilitate immuno-oncology studies, a humanized SRG Model – the ImmunoRatTM – is in development.  We’re continuing to use our proprietary Cas-CLOVERTM CRISPR System and piggyBacTM gene-editing technologies and know-how to expand our robust pipeline of animal models and services.

As a spinout of Transposagen Biopharmaceuticals, Inc., Hera BioLabs is based in Lexington, KY.  Our vivarium features a dual HEPA-filtered, disposable IVC rodent caging system, and the facility has successfully passed multiple audits by our happy clients.  Pre-clinical research services are provided by Hera’s knowledgeable, friendly, customer-focused team.